Abstract Search

ea0081p140 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Benderradji Hamza , Elise Vernotte , Ares Gustave Soto , Jean Philippe Woillez , Romain Perbet , Melodie-Anne Karnoub , Benoit Soudan , Arnaud Jannin , Assaker Richard , Luc Buee , Prevot Vincent , Claude-Alain Maurage , Pascal Pigny , Marie-Christine Vantyghem , Emilie Merlen , Cortet Rudelli Christine

Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and patients: This single-center retrospective study included 21 patients who were newly diagno...

0 shares

ea0094p371 | Neuroendocrinology and Pituitary | SFEBES2023

GnRH neuronal disruption and hypotestosteronemia in COVID-19

Sauve Florent , Nampoothiri Sreekala , Clarke Sophie , Fernandois Daniela , Fernando Ferreira Coelho Caio , Dewisme Julie , G Mills Edouard , Ternier Gaetan , Cotellessa Ludovica , Iglesias Garcia Cristina , Mueller-Fielitz Helge , Lebouvier Thibaud , Perbet Romain , Florent Vincent , Baroncini Marc , Sharif Ariane , Ereno-Orbea June , Mercado-Gomez Maria , Palazon Asis , Mattot Virginie , Pasquier Florence , Catteau-Jonard Sophie , Martinez-Chantar Maria , Hrabovszky Erik , Jourdain Merce , Deplanque Dominique , Morelli Annamaria , Guarnier Giulia , Storme Laurent , Robil Cyril , Trottein Francois , Nogueiras Ruben , Schwaninger Markus , Pigny Pascal , Poissy Julien , Chachlaki Konstantina , Maurage Claude-Alain , Giacobini Paolo , S Dhillo Waljit , Rasika S , Prevot Vincent

Loss of gonadotropin-releasing hormone (GnRH) and cognitive deficits have recently been demonstrated by our group in conditions including Down syndrome and Alzhiemers disease. In some patients with COVID-19, olfactory and cognitive alterations persist, and persistent hypotestosteronemia in SARS-CoV-2-infected men could be a consequence of deficient GnRH. To understand whether neuroinvasion of GnRH system by SARS-CoV-2 could explain some post-COVID symptoms and thus resul...

0 shares

Endocrine Abstracts

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

GnRH neuronal disruption and hypotestosteronemia in COVID-19

BiosciAbstracts